Genetically engineered T cells for cancer immunotherapy

作者：Dan Li, Xue Li, Weilin Zhou, Yong Huang, Xiao Liang, Lin Jiang, Xiao Wei Yang, Jie Sun, Zonghai Li, Weidong Han, Wei Wang · 发表于：Signal Transduction and Targeted Therapy · 年份：2019 · DOI：10.1038/s41392-019-0070-9 · 被引用次数：249 · 研究领域：CAR-T cell therapy research、Virus-based gene therapy research、Immune Cell Function and Interaction

T cells in the immune system protect the human body from infection by pathogens and clear mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy, by relying on this basic recognition method, boosts the antitumor efficacy of T cells by unleashing the inhibition of immune checkpoints and expands adaptive immunity by facilitating the adoptive transfer of genetically engineered T cells. T cells genetically equipped with chimeric antigen receptors (CARs) or TCRs have shown remarkable effectiveness in treating some hematological malignancies, although the efficacy of engineered T cells in treating solid tumors is far from satisfactory. In this review, we summarize the development of genetically engineered T cells, outline the most recent studies investigating genetically engineered T cells for cancer immunotherapy, and discuss strategies for improving the performance of these T cells in fighting cancers.